Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $165.

January 22, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals and maintained a $165 price target.
The reiteration of a Neutral rating and maintenance of the price target suggests that Cantor Fitzgerald's view on Alnylam Pharmaceuticals has not changed. This is likely to have a neutral short term impact on the stock as it does not alter the investment thesis or provide new information that would significantly change the market's perception of the company's value.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100